ECSP11011241A - Sistemas basados en conjugados para entrega farmacológica controlada - Google Patents
Sistemas basados en conjugados para entrega farmacológica controladaInfo
- Publication number
- ECSP11011241A ECSP11011241A EC2011011241A ECSP11011241A ECSP11011241A EC SP11011241 A ECSP11011241 A EC SP11011241A EC 2011011241 A EC2011011241 A EC 2011011241A EC SP11011241 A ECSP11011241 A EC SP11011241A EC SP11011241 A ECSP11011241 A EC SP11011241A
- Authority
- EC
- Ecuador
- Prior art keywords
- certain embodiments
- saccharide
- glucose
- ligands
- conjugates
- Prior art date
Links
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 5
- 239000008103 glucose Substances 0.000 abstract 5
- 239000003446 ligand Substances 0.000 abstract 5
- 102000004877 Insulin Human genes 0.000 abstract 4
- 108090001061 Insulin Proteins 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940125396 insulin Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 2
- 108010062580 Concanavalin A Proteins 0.000 abstract 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 abstract 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En un aspecto, la divulgación proporciona métodos para controlar los perfiles farmacocinéticos (PK) y/o farmacodinámicos (PD) de insulina en una forma que es sensible a las concentraciones sistémicas de un sacárido tal como la glucosa. Como se discutió en los Ejemplos, se descubrió que cuando la insulina fuera conjugada con ligandos sacáridos de alta afinidad, pudo hacerse exhibir perfiles PK/PD que respondieran a cambios de concentración sacárida aún en ausencia de una molécula multivalente y exógena fijadora de sacáridos tal como Con A. Este hallazgo fue inesperado y proporciona una oportunidad sin precedentes para generar sistemas simples de insulina sensibles a sacáridos libres de lectina. En otro aspecto, la divulgación proporciona conjugados y métodos de ejemplo para la fabricación de los mismos. En general, estos conjugados incluyen un fármaco y uno o más ligandos separados en donde cada uno incluye un sacárido. En ciertas realizaciones, los ligandos son capaces de competir con un sacárido (por ejemplo, glucosa o manosa) para unirse a una molécula fijadora de sacáridos endógenos. En ciertas realizaciones, los ligandos son capaces de competir con la glucosa o manosa por la unión a Con A. Como se explica en detalle más adelante, en ciertas realizaciones, los ligandos y el fármaco pueden estar covalente o no covalentemente unidos a una estructura de conjugado. En ciertas realizaciones, la estructura es no polimérica. En ciertas realizaciones, un conjugado puede tener un índice de polidispersidad de uno y un peso molecular de menos de 20.000 Da aproximadamente. En ciertas realizaciones, el conjugado es de larga duración (es decir, presenta un perfil farmacocinético que es más sostenido que la insulina humana recombinante soluble o RHI).Como está discutido en detalle más adelante, se debe entender que los métodos, conjugados y formulaciones que se describen en este documento no están limitados de ninguna manera a solamente la entrega de insulina y se debe entender que pueden ser utilizados para liberar cualquier medicamento. También se debe entender que los métodos se pueden utilizar para liberar fármacos en respuesta a sacáridos diferentes de la glucosa. En particular, como se indica en los ejemplos, se ha demostrado que los conjugados de ejemplo responden a sacáridos exógenos como el alfa- metil manosa y L- fucosa. En ciertas realizaciones, esto puede utilizarse para preparar conjugados que pueden ser controlados por la administración de uno de estos sacáridos exógenos (es decir, en lugar de o además de ser controlados por las fluctuaciones en la glucosa endógena).
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14787809P | 2009-01-28 | 2009-01-28 | |
| US15964309P | 2009-03-12 | 2009-03-12 | |
| US16210709P | 2009-03-20 | 2009-03-20 | |
| US16308409P | 2009-03-25 | 2009-03-25 | |
| US21989709P | 2009-06-24 | 2009-06-24 | |
| US21989609P | 2009-06-24 | 2009-06-24 | |
| US22357209P | 2009-07-07 | 2009-07-07 | |
| US25285709P | 2009-10-19 | 2009-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011241A true ECSP11011241A (es) | 2011-11-30 |
Family
ID=42395990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011241A ECSP11011241A (es) | 2009-01-28 | 2011-07-28 | Sistemas basados en conjugados para entrega farmacológica controlada |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8906850B2 (es) |
| EP (1) | EP2391646B1 (es) |
| JP (1) | JP2012516342A (es) |
| KR (2) | KR20140054404A (es) |
| CN (1) | CN102341409A (es) |
| AU (1) | AU2010208319A1 (es) |
| BR (1) | BRPI1007466A2 (es) |
| CA (1) | CA2750269A1 (es) |
| CO (1) | CO6400230A2 (es) |
| EC (1) | ECSP11011241A (es) |
| IL (1) | IL214126A0 (es) |
| MX (1) | MX2011007930A (es) |
| PE (1) | PE20120582A1 (es) |
| RU (1) | RU2011135730A (es) |
| SG (1) | SG173117A1 (es) |
| WO (1) | WO2010088300A1 (es) |
| ZA (1) | ZA201105462B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010088268A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
| US8940690B2 (en) | 2009-01-28 | 2015-01-27 | National Institutes Of Health (Nih) | Synthetic conjugates and uses thereof |
| US9050370B2 (en) * | 2009-01-28 | 2015-06-09 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
| US9095623B2 (en) | 2009-03-20 | 2015-08-04 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| WO2010107519A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| CA2805902A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
| WO2012015692A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| AU2011282977A1 (en) * | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| AU2011282983A1 (en) * | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| CN102188367B (zh) * | 2011-01-05 | 2012-11-07 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
| US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
| US9884125B2 (en) * | 2013-10-04 | 2018-02-06 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| EP3167393B1 (en) | 2014-07-10 | 2019-11-06 | Companion Medical Inc. | Medicine administering system including injection pen and companion device |
| EP3280450A4 (en) * | 2015-04-08 | 2018-12-12 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| JP6856546B2 (ja) | 2015-04-21 | 2021-04-07 | ノース カロライナ ステート ユニバーシティＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ | 低酸素感受性ナノコンポジットを用いたグルコース応答性インスリン送達システム |
| US10946102B2 (en) * | 2016-01-14 | 2021-03-16 | North Carolina State University | Glucose responsive insulin delivery compositions and methods |
| US10864327B2 (en) | 2016-01-29 | 2020-12-15 | Companion Medical, Inc. | Automatic medication delivery tracking |
| BR112018074716A2 (pt) * | 2016-06-02 | 2019-03-12 | Sanofi | conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose |
| CN110167537A (zh) | 2016-11-07 | 2019-08-23 | 北卡罗来纳州立大学 | 用于增强葡萄糖反应性胰岛素的递送的装有双敏感囊泡的贴剂 |
| US11484657B2 (en) | 2017-06-09 | 2022-11-01 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods |
| EP3694583A4 (en) * | 2017-10-12 | 2021-08-04 | Companion Medical, Inc. | INTELLIGENT DRUG DELIVERY SYSTEMS AND METHODS FOR DOSAGE RECOMMENDATION AND ADMINISTRATION |
| KR20200095507A (ko) | 2017-12-01 | 2020-08-10 | 사노피 | 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 신규 접합체 |
| US11197964B2 (en) | 2017-12-12 | 2021-12-14 | Bigfoot Biomedical, Inc. | Pen cap for medication injection pen having temperature sensor |
| WO2019118532A1 (en) | 2017-12-12 | 2019-06-20 | Bigfoot Biomedical, Inc. | Medicine injection and disease management systems, devices, and methods |
| US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
| US11083852B2 (en) | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
| US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
| US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
| US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
| US11413352B2 (en) * | 2017-12-18 | 2022-08-16 | Merck, Sharp & Dohme LLC | Conjugate based systems for controlled insulin delivery |
| WO2019125878A1 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Conjugate based systems for controlled insulin delivery |
| US11664107B2 (en) | 2018-05-08 | 2023-05-30 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods using a prescription-regulated software application |
| US10898653B2 (en) | 2018-05-08 | 2021-01-26 | Companion Medical, Inc. | Intelligent medication delivery systems and methods for dose setting and dispensing monitoring |
| USD893020S1 (en) | 2018-05-11 | 2020-08-11 | Companion Medical, Inc. | Injection pen |
| USD892819S1 (en) | 2018-06-20 | 2020-08-11 | Companion Medical, Inc. | Display screen with graphical user interface |
| US11587663B2 (en) | 2018-06-20 | 2023-02-21 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods for medicine dose calculation and reporting |
| CN110922437B (zh) * | 2018-09-20 | 2023-11-03 | 凯惠科技发展(上海)有限公司 | 一种葡萄糖类化合物、药物组合物及其应用 |
| US12205699B1 (en) | 2018-10-30 | 2025-01-21 | Bigfoot Biomedical, Inc. | Method of pairing therapy devices using shared secrets, and related systems, methods and devices |
| US11948671B2 (en) | 2019-04-11 | 2024-04-02 | Medtronic Minimed, Inc. | Intelligent accessories for medicine dispensing device |
| EP4003405A4 (en) * | 2019-07-30 | 2023-08-23 | Merck Sharp & Dohme LLC | GLUCOSE-RESPONDING INSULIN CONJUGATES |
| US11701473B2 (en) | 2021-06-23 | 2023-07-18 | Medtronic Minimed, Inc. | Reusable injection pens |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3591574A (en) | 1968-05-29 | 1971-07-06 | American Home Prod | Tri-n-phenylglycyl derivatives of insulin |
| DE1793517C3 (de) | 1968-09-28 | 1974-12-05 | Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt | N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung |
| US3847890A (en) | 1971-11-01 | 1974-11-12 | A Green | Acidic monosaccharide-substituted proteins |
| DE2964024D1 (en) | 1978-10-02 | 1982-12-16 | Procter & Gamble | Liposomes for drug delivery and composition containing a liposome drug system |
| US4377567A (en) | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
| US4348387A (en) | 1979-07-31 | 1982-09-07 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
| JPS608000B2 (ja) | 1980-04-11 | 1985-02-28 | 呉羽化学工業株式会社 | アミノフエニル誘導体及び該誘導体を含有する生理活性剤 |
| US4444683A (en) | 1982-11-17 | 1984-04-24 | University Of Utah | Glycosylated insulin derivatives |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| EP0119650A3 (en) | 1983-03-21 | 1987-09-30 | THE PROCTER & GAMBLE COMPANY | Galactosyl-insulin conjugates useful in treating diabetics |
| US4863896A (en) | 1984-05-03 | 1989-09-05 | Technology Unlimited, Inc. | Diabetic control by combined insulin forms |
| US5239062A (en) | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
| US5395924A (en) | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
| US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
| DK111489D0 (da) | 1989-03-08 | 1989-03-08 | Novo Nordisk As | Peptider |
| AU628674B2 (en) | 1989-10-19 | 1992-09-17 | Nippon Oil And Fats Company, Limited | Polymer complexes of a sugar response type |
| GB9200638D0 (en) | 1992-01-10 | 1992-03-11 | Leicester Polytechnic | Drug system |
| DE69328523T2 (de) | 1992-02-13 | 2000-09-21 | Surmodics, Inc. | Immobilisierung eines chemischen spezies in einer vernetzten matrix |
| GB9316895D0 (en) | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
| GB9313484D0 (en) | 1993-06-30 | 1993-08-11 | Univ Montfort | Drug system ii |
| US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| JP2000501414A (ja) | 1995-11-22 | 2000-02-08 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 生体分子の細胞取り込みを高めるリガンド |
| US5723589A (en) | 1995-12-21 | 1998-03-03 | Icn Pharmaceuticals | Carbohydrate conjugated bio-active compounds |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| EP0954589A1 (en) | 1997-01-24 | 1999-11-10 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
| EP1071703B1 (en) | 1998-04-15 | 2005-07-20 | Novo Nordisk A/S | NOVEL PROCESS FOR THE SEPARATION OF PROTEINS USING A Ca++ CONTAINING ELUANT |
| US6844166B1 (en) | 1998-09-11 | 2005-01-18 | Sensor Technologies Inc. | Recombinant reduced valency carbohydrate binding ligands |
| US6323311B1 (en) | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
| US6777207B2 (en) | 1999-12-29 | 2004-08-17 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast |
| US6521738B2 (en) | 1999-12-29 | 2003-02-18 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogs |
| EP1290024A1 (en) | 2000-06-02 | 2003-03-12 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| US7316999B2 (en) | 2000-06-02 | 2008-01-08 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US20020192182A1 (en) | 2001-03-12 | 2002-12-19 | Stephen Massia | Polysaccharide-based polymerizable hydrogels |
| US7105314B2 (en) | 2001-04-02 | 2006-09-12 | Novo Nordisk A/S | Method for making human insulin precursors |
| EP1446163A4 (en) | 2001-10-26 | 2006-01-04 | Uab Research Foundation | MULTIDRUG MULTILIGAND CONJUGATES FOR THE TARGETED DELIVERY OF MEDICAMENTS |
| US7317000B2 (en) | 2001-12-02 | 2008-01-08 | Novo Nordisk A/S | Glucose-dependent insulins |
| EP1452950A4 (en) | 2001-12-07 | 2009-07-08 | Ntt Docomo Inc | MOBILE COMMUNICATION SENDING DEVICE, METHOD FOR CONTROLLING THE PERFORMANCE OF AN APPLICATION PROGRAM, APPLICATION PROGRAM AND RECORDING MEDIA RECORDED FOR AN APPLICATION PROGRAM |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| EP1545462A4 (en) * | 2002-07-19 | 2007-08-08 | Univ California | DENDRIMERS AS MOLECULAR TRANSLOCATORS |
| CA2509382A1 (en) | 2002-12-17 | 2004-07-08 | Todd C. Zion | Stimuli-responsive systems for controlled drug delivery |
| WO2004057002A2 (en) | 2002-12-20 | 2004-07-08 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| JPWO2004101619A1 (ja) | 2003-05-15 | 2006-10-26 | 塩野義製薬株式会社 | 機能的糖ペプチドの合理的設計および合成 |
| US20080102114A1 (en) | 2004-04-23 | 2008-05-01 | Panduranga Rao Koritala | Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents |
| WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
| MX2007000883A (es) * | 2004-07-19 | 2007-04-02 | Biocon Ltd | Conjugados de insulina-oligomero, formulaciones y usos de los mismos. |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| US20090036353A1 (en) * | 2005-01-27 | 2009-02-05 | Novo Nordisk A/S | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers |
| TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
| US20060247154A1 (en) | 2005-02-24 | 2006-11-02 | Lifescan, Inc. | Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same |
| US20070207498A1 (en) | 2005-02-24 | 2007-09-06 | Lifescan, Inc. | Design and construction of dimeric concanavalin a mutants |
| WO2006102762A1 (en) | 2005-04-01 | 2006-10-05 | Mcmaster University | Glucose responsive microgels |
| JP2009511544A (ja) | 2005-10-10 | 2009-03-19 | ナームローゼ・フエンノートチヤツプ・オルガノン | 抗血栓化合物 |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| WO2007047922A2 (en) * | 2005-10-19 | 2007-04-26 | Smartcells, Inc. | Polymer-drug conjugates |
| DE602007009496D1 (de) | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
| US20100189643A1 (en) | 2006-07-24 | 2010-07-29 | Duke University | Drug delivery with stimulus responsive biopolymers |
| JP2009544680A (ja) | 2006-07-25 | 2009-12-17 | リポクセン テクノロジーズ リミテッド | ポリサッカライドによるタンパク質のｎ末端誘導体化 |
| FR2904315B1 (fr) | 2006-07-26 | 2012-12-14 | Centre Nat Rech Scient | Composes pyridaziniques et pyrroliques, procedes d'obtention et applications |
| CN101273961A (zh) | 2007-03-30 | 2008-10-01 | 中国人民解放军总医院 | 葡萄糖敏感水凝胶 |
| US20090053167A1 (en) | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
| WO2009033588A2 (en) | 2007-09-11 | 2009-03-19 | F. Hoffmann-La-Roche Ag | Self-controlled insulin delivery system |
| WO2009059450A1 (en) | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
| WO2009089396A2 (en) | 2008-01-08 | 2009-07-16 | Neose Technologies, Inc. | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| RU2381238C2 (ru) | 2008-01-31 | 2010-02-10 | Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) | Способ получения глюкозочувствительных полимерных гидрогелей |
| EP2242767A4 (en) | 2008-02-19 | 2011-04-06 | Biocon Ltd | PROCESS FOR OBTAINING PURIFIED HETEROLOGOUS INSULINS EXPRESSED IN YEASTS |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
-
2010
- 2010-01-27 BR BRPI1007466A patent/BRPI1007466A2/pt not_active IP Right Cessation
- 2010-01-27 EP EP10736359.0A patent/EP2391646B1/en active Active
- 2010-01-27 JP JP2011548261A patent/JP2012516342A/ja active Pending
- 2010-01-27 KR KR1020147008437A patent/KR20140054404A/ko not_active Withdrawn
- 2010-01-27 SG SG2011053378A patent/SG173117A1/en unknown
- 2010-01-27 PE PE2011001412A patent/PE20120582A1/es not_active Application Discontinuation
- 2010-01-27 US US13/145,525 patent/US8906850B2/en active Active
- 2010-01-27 WO PCT/US2010/022277 patent/WO2010088300A1/en not_active Ceased
- 2010-01-27 KR KR1020117017642A patent/KR20110110253A/ko not_active Abandoned
- 2010-01-27 CA CA2750269A patent/CA2750269A1/en not_active Abandoned
- 2010-01-27 RU RU2011135730/04A patent/RU2011135730A/ru not_active Application Discontinuation
- 2010-01-27 AU AU2010208319A patent/AU2010208319A1/en not_active Abandoned
- 2010-01-27 CN CN201080009857XA patent/CN102341409A/zh active Pending
- 2010-01-27 MX MX2011007930A patent/MX2011007930A/es not_active Application Discontinuation
-
2011
- 2011-07-17 IL IL214126A patent/IL214126A0/en unknown
- 2011-07-25 ZA ZA2011/05462A patent/ZA201105462B/en unknown
- 2011-07-28 CO CO11095151A patent/CO6400230A2/es active IP Right Grant
- 2011-07-28 EC EC2011011241A patent/ECSP11011241A/es unknown
-
2014
- 2014-05-19 US US14/280,793 patent/US9463249B2/en active Active
-
2016
- 2016-10-07 US US15/288,362 patent/US20170022262A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170022262A1 (en) | 2017-01-26 |
| EP2391646B1 (en) | 2016-08-10 |
| US9463249B2 (en) | 2016-10-11 |
| PE20120582A1 (es) | 2012-05-26 |
| RU2011135730A (ru) | 2013-03-10 |
| EP2391646A1 (en) | 2011-12-07 |
| CO6400230A2 (es) | 2012-03-15 |
| KR20140054404A (ko) | 2014-05-08 |
| ZA201105462B (en) | 2015-01-28 |
| US8906850B2 (en) | 2014-12-09 |
| CA2750269A1 (en) | 2010-08-05 |
| WO2010088300A1 (en) | 2010-08-05 |
| US20110281791A1 (en) | 2011-11-17 |
| CN102341409A (zh) | 2012-02-01 |
| JP2012516342A (ja) | 2012-07-19 |
| SG173117A1 (en) | 2011-08-29 |
| BRPI1007466A2 (pt) | 2018-06-12 |
| AU2010208319A1 (en) | 2011-08-11 |
| MX2011007930A (es) | 2011-09-06 |
| US20140275476A1 (en) | 2014-09-18 |
| IL214126A0 (en) | 2011-08-31 |
| EP2391646A4 (en) | 2012-06-27 |
| KR20110110253A (ko) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011241A (es) | Sistemas basados en conjugados para entrega farmacológica controlada | |
| DOP2011000244A (es) | Sistemas basados en conjugados para entrega farmacologica controlada | |
| Yang et al. | Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery | |
| BR112016007176A2 (pt) | conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete | |
| Wang et al. | Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles | |
| Gao et al. | Drug nanocrystals: in vivo performances | |
| Kou et al. | Cotransporting Ion is a Trigger for Cellular Endocytosis of Transporter‐Targeting Nanoparticles: A Case Study of High‐Efficiency SLC22A5 (OCTN2)‐Mediated Carnitine‐Conjugated Nanoparticles for Oral Delivery of Therapeutic Drugs | |
| AR081042A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g | |
| Belletti et al. | Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin | |
| Camacho et al. | Low-molecular-weight polymer–drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations | |
| Buckley et al. | Chemically modified peptides and proteins-critical considerations for oral delivery | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| WO2012170372A3 (en) | Prna mutlivalent junction domain for use in stable multivalent rna nanoparticles | |
| AR100695A1 (es) | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón | |
| BRPI0607549A2 (pt) | sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos | |
| MY176834A (en) | Conjugate biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same | |
| JP2018513843A5 (es) | ||
| JP2016533348A5 (es) | ||
| BR112015017246A8 (pt) | composição farmacêutica aquosa, seu uso e seringa | |
| Quan et al. | Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44 | |
| Gul et al. | Functionalised nanostructures for transdermal delivery of drug cargos | |
| US20140079738A1 (en) | Self-gelatinizable nucleic acid | |
| BR112015024659A2 (pt) | tratamento de diabetes mellitus por formulações de ação prolongada de insulinas | |
| BR112013006088A2 (pt) | Construto de entrega isolado, e, composição farmacêuticapolinucleotídeo que encodifica um construtor de entrega, vetor de expressão, e célula hospedeira isolada" | |
| BR112013022170A2 (pt) | composições de vesícula |